 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || ZY T1 / Zydus Cadila
Clinical, Journal: ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer. (Pubmed Central) - Jun 4, 2021
It also reduced the growth of TMD8 xenograft tumor. The results suggested that ZYBT1 has high potential for treating RA, and cancer.
- ZY T1 / Zydus Lifesci
Enrollment change, Trial termination, Trial primary completion date: A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers (clinicaltrials.gov) - Nov 24, 2015
P1, N=24, Terminated, Sponsor: Cadila Healthcare Limited
The results suggested that ZYBT1 has high potential for treating RA, and cancer. N=112 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Jul 2012; Safety concerns
- || ZY T1 / Zydus Lifesci
Enrollment closed: A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers (clinicaltrials.gov) - Oct 24, 2013
P1, N=112, Active, not recruiting, Sponsor: Cadila Healthcare Limited
N=112 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Jul 2012; Safety concerns Recruiting --> Active, not recruiting
- ||| ZY T1 / Zydus Lifesci
New P1 trial: A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers (clinicaltrials.gov) - Feb 29, 2012
P1, N=112, Active, not recruiting, Sponsor: Cadila Healthcare Limited